Skip to content
CancerIndex

Publication

Design, synthesis, and structural optimization of novel pan-KRAS degrader for the treatment of KRAS-mutant pancreatic cancer.

Shenxin Zeng, Yiqing Zhao, Yangqing Liu, Yaokang Shen, Zixin Zhu, Beijing Chen, Xian Li, Leyuan Zhang, Jingyu Zhang, Yingchen Zhu, Pei Liu, Yubo Zhou, Wenhai Huang

European journal of medicinal chemistrySep 24, 2026PMID 42800113doi:10.1016/j.ejmech.2026.119362 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

KRAS, a frequently mutated oncogene, has been demonstrated to harbor multiple mutant variants. Although KRAS G12C inhibitors have been successfully approved for clinical use, their efficacy remains limited by acquired resistance and narrow patient eligibility. Here, we leveraged the…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.